MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$38,729K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Deferred revenue
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Accrued liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-31,918
-41,488
-35,896
-16,700
Depreciation and amortization
110
111
107
125
Loss on disposal of property and equipment
-
-
0
-
Loss on impairment of operating right-of-use assets and related property and equipment
0
0
0
0
Accretion of discounts and amortization of premiums on marketable securities, net
131
316
608
779
Gain on long-term investments
0
-
-197
-
Change in fair value of preferred stock warrants
-
-
0
0
Write-off of nonsalable inventory
0
414
-
-
Share-based compensation expense
4,472
4,319
3,678
3,469
Accounts receivable, net
99
14
329
-
Inventory
-19
889
3,326
949
Prepaid expenses and other current assets
2,575
341
1,924
-93
Accounts payable
-4,281
6,762
-156
1,694
Accrued liabilities
-5,110
-2,114
5,029
4,459
Deferred revenue
785
-
-
-
Operating lease liabilities, net
-5
-27
-
-
Other assets
-20
-1
-203
0
Net cash used in operating activities
-38,713
-33,582
-33,025
-8,588
Purchases of marketable securities
7,374
16,056
133,112
56,306
Proceeds from maturities of marketable securities
45,144
49,235
43,340
52,412
Purchases of property and equipment
16
18
38
439
Net cash provided by investing activities
37,754
33,161
-89,810
-4,333
Proceeds from issuance of common stock through at-the-market offerings, net of issuance costs
0
-
121,682
0
Proceeds from exercises of stock options
0
14
285
598
Proceeds from issuance of common stock under employee stock purchase plan
395
-
648
0
Cash, cash equivalents, and restricted cash acquired in connection with the merger
-
-
0
0
Proceeds from issuance of common stock, net of issuance costs-Private Placement
-
-
0
0
Merger transaction costs
-
-
0
0
Net cash provided by financing activities
395
14
122,615
598
Net (decrease) increase in cash, cash equivalents and restricted cash
-564
-407
-220
-12,323
Cash, cash equivalents, and restricted cash, beginning of the period
-
-
25,399
20,272
Cash, cash equivalents and restricted cash, beginning of the period
24,772
25,179
-
-
Cash, cash equivalents, and restricted cash, end of the period
-
-
25,179
25,399
Cash, cash equivalents and restricted cash, end of the period
24,208
24,772
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$45,144K
(-59.04%↓ Y/Y)
Proceeds from issuance of
common stock under...
$395K
(75.56%↑ Y/Y)
Net cash provided by
investing activities
$37,754K
(104.35%↑ Y/Y)
Net cash provided by
financing activities
$395K
(-98.51%↓ Y/Y)
Canceled cashflow
$7,390K
Net (decrease)
increase in cash, cash...
-$564K
(-103.23%↓ Y/Y)
Canceled cashflow
$38,149K
Share-based compensation
expense
$4,472K
(-17.19%↓ Y/Y)
Deferred revenue
$785K
Depreciation and
amortization
$110K
(100.00%↑ Y/Y)
Other assets
-$20K
(-109.80%↓ Y/Y)
Inventory
-$19K
Purchases of marketable
securities
$7,374K
(-91.93%↓ Y/Y)
Purchases of property and
equipment
$16K
(-95.43%↓ Y/Y)
Net cash used in
operating activities
-$38,713K
(-40.48%↓ Y/Y)
Canceled cashflow
$5,406K
Net loss
-$31,918K
(-8.08%↓ Y/Y)
Accrued liabilities
-$5,110K
(-443.64%↓ Y/Y)
Accounts payable
-$4,281K
(-162.96%↓ Y/Y)
Prepaid expenses and
other current assets
$2,575K
(115.30%↑ Y/Y)
Accretion of discounts and
amortization of premiums on...
$131K
(-93.52%↓ Y/Y)
Accounts receivable, net
$99K
Operating lease
liabilities, net
-$5K
Buy us a coffee
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)